• Contact Us
  • Careers
Sound Pharmaceuticals
  • Team
    • Leadership
    • Board of Directors
    • Advisors
  • Neurotology
  • Technology
  • Pipeline
  • News
Aug 31
Love0

FDA allows Sound Pharmaceuticals to test SPI-1005 as a novel treatment for COVID-19

By Jim News Short

Sound Pharmaceuticals, Inc. (SPI) is pleased to announce that the FDA has allowed two Phase 2 studies to begin testing ebselen (SPI-1005) in COVID-19 patients. SPI is developing SPI-1005, a novel anti-inflammatory drug which was recently shown to inhibit nCoV2 activity and viral replication.
Read More

Jul 30
Love0

Sound Pharmaceuticals files IND to test SPI-1005 in Phase 2 COVID-19 trials

By Jim News Short

Sound Pharmaceuticals (SPI) is pleased to announce the filing of an Investigational New Drug Application with the FDA to begin Phase 2 studies to prevent and treat COVID-19.
Read More

Jun 08
Love0

Sound Pharmaceuticals advances pivotal Phase 3 clinical trials in Meniere’s Disease

By Jim News Short

Sound Pharmaceuticals is pleased to announce that the FDA has allowed its pivotal Phase 3 clinical protocol for SPI-1005 in the Treatment of Patients with Meniere’s Disease (STOPMD-3). Read More

May 04
Love0

University of Oxford and Sound Pharmaceuticals complete Phase 2 Bipolar Disorder Study with SPI-1005

By Jim News Short

TheĀ University of Oxford and Sound Pharmaceuticals (SPI), are pleased to announce the successful completion of a Phase 2a study testing SPI-1005 as a new treatment for bipolar disorder (BPD). Read More

Sep 18
Love0

FDA grants Fast Track Designation for SPI-1005 in the Treatment of Meniere’s Disease

By Jim News Short

SEATTLE — Sound Pharmaceuticals is pleased to announce that the FDA’s Division of Neurology Products has granted its request for Fast Track Designation (FTD) involving SPI-1005 in the treatment of Meniere’s Disease (MD).

Read More

Jun 25
Love0

Sound Pharmaceuticals announces positive topline results from the SPI-1005 Phase 2b Meniere’s Disease clinical trial

By Jim News Short

SPI-1005 hits pre-specified endpoints resulting in a significant improvement in hearing loss of 65% and 95% relative to placebo

Read More

Mar 20
Love0

Sound Pharmaceuticals announces completion of patient enrollment in the Phase 2b Meniere’s Disease clinical trial

By Jim News Short

Read More

Jan 14
Love0

Sound Pharmaceuticals advances Phase 2 hearing loss clinical trial in Cystic Fibrosis

By Jim News Short

Read More

Oct 18
Love0

Sound Pharmaceuticals to Present Preliminary Data on Ototoxicity Study

By Jim News Short

Read More

Nov 01
Love0

University of Oxford and Sound Pharmaceuticals begin Phase 2 clinical trial on novel treatment for bipolar disorder

By Jim News Short

Read More

1 2 3 … 5 Next

Archives

Contact Us

Address:

4010 Stone Way N # 120
Seattle, WA 98103

Phone:

(206) 634-2559

Email:

info@soundpharma.com

Disclosures

Legal & Terms

Other resources

Links
High-Res Logo

All Rights Reserved, Sound Pharmaceuticals.

  • Team
    • Leadership
    • Board of Directors
    • Advisors
  • Neurotology
  • Technology
  • Pipeline
  • News
  • Contact Us
  • Careers